Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age.
Mirna ChehadeEvan S DellonJonathan M SpergelMargaret H CollinsMarc E RothenbergRobert D PesekIkuo HiranoRuiqi LiuElizabeth LawsEric MortensenRenata MartincovaArsalan ShabbirEilish McCannMohamed A KamalMatthew P KosloskiJennifer D HamiltonCarin SamuelyWei Keat LimMatthew F WippermanAnnamaria FarrellNaimish PatelGeorge D YancopoulosLila GlotfeltyJennifer MaloneyPublished in: The New England journal of medicine (2024)
Dupilumab resulted in histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo. The higher-exposure dupilumab regimen also led to improvements in measures of key secondary end points as compared with placebo. (Funded by Sanofi and Regeneron Pharmaceuticals; EoE KIDS ClinicalTrials.gov number, NCT04394351.).